Siricidae

Strongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue

Retrieved on: 
Thursday, July 29, 2021
SEC filings, Initial public offering, Prospectus, Corporate finance, Siricidae, Financial markets, Proxy statement, Proxy, Xeris, Financial economics

Strongbridge, Xeris andHoldCohave prepared and filed with theSECa preliminary joint proxy statement/prospectus onJuly 2, 2021 and Amendment No.

Key Points: 
  • Strongbridge, Xeris andHoldCohave prepared and filed with theSECa preliminary joint proxy statement/prospectus onJuly 2, 2021 and Amendment No.
  • 333-257642) which also constitutes a prospectus with respect to theHoldCoshares of common stock (HoldCo Shares) to be issued pursuant to the Transaction.
  • This communication is not a substitute for the joint proxy statement/prospectus or any other document which Strongbridge, Xeris orHoldComay file with theSEC.
  • Terms in single quotation marks are defined in the Irish Takeover Rules, which can also be found on the Panels website.

Xeris Pharmaceuticals Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue

Retrieved on: 
Thursday, July 29, 2021
Health, Pharmaceutical, Financial markets, Corporate finance, Financial economics, Finance, Stock market, Equity securities, Mergers and acquisitions, Siricidae, Convertible security, Convertible bond, Xeris, Stock

Upon exercise, each Xeris Stock Option entitles the holder to purchase one share of common stock at the applicable exercise price.

Key Points: 
  • Upon exercise, each Xeris Stock Option entitles the holder to purchase one share of common stock at the applicable exercise price.
  • Upon conversion of the Xeris Convertible Notes, up to 15,416,667 shares of Xeris common stock may be issued.
  • A disclosure table, giving details of the companies in whose relevant securities dealings should be disclosed, can be found on the Irish Takeover Panels website at www.irishtakeoverpanel.ie .
  • Terms in single quotation marks are defined in the Irish Takeover Rules, which can also be found on the Irish Takeover Panels website.

STRONGBRIDGE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Strongbridge Biopharma plc - SBBP

Retrieved on: 
Friday, May 28, 2021
Legal, Professional services, Articles, Siricidae, Foti, KSF, Limited liability company, Share, Generation X, Xeris

and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Strongbridge Biopharma plc (NasdaqGS: SBBP) to Xeris Pharmaceuticals, Inc. (NasdaqGS: XERS).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Strongbridge Biopharma plc (NasdaqGS: SBBP) to Xeris Pharmaceuticals, Inc. (NasdaqGS: XERS).
  • Under the terms of the proposed transaction, shareholders of Strongbridge will receive only 0.7840 shares of Xeris plus one contingent value right for each share of Strongbridge that they own.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

Rule 2.5 Announcement: Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma Plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases

Retrieved on: 
Monday, May 24, 2021
Biotechnology, Pharmaceutical, Health, Siricidae, Xeris, Xeris Pharmaceuticals, Inc., Xeris Biopharma Holdings, Inc., Strongbridge Biopharma plc, XERIS PHARMACEUTICALS, INC., XERIS BIOPHARMA HOLDINGS, INC., STRONGBRIDGE BIOPHARMA PLC

Upon close of the transaction, the businesses of Xeris and Strongbridge will be combined under a new entity to be called Xeris Biopharma Holdings, Inc. (Xeris Biopharma Holdings).

Key Points: 
  • Upon close of the transaction, the businesses of Xeris and Strongbridge will be combined under a new entity to be called Xeris Biopharma Holdings, Inc. (Xeris Biopharma Holdings).
  • The minimum payment on the CVR is zero and the maximum payment is $1.00 in cash or Xeris Biopharma Holdings Shares at Xeris Biopharma Holdings' election.
  • The combination of Xeris and Strongbridge is expected to deliver compelling strategic and financial benefits including:
    Diversified and Increased Revenue Growth.
  • On close, Xeris shareholders will exchange each Xeris Share they own for 1 Xeris Biopharma Holdings Share.

Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases

Retrieved on: 
Monday, May 24, 2021
Biotechnology, Pharmaceutical, Health, Siricidae, Xeris, Xeris Pharmaceuticals, Inc., Strongbridge Biopharma, XERIS PHARMACEUTICALS, INC., STRONGBRIDGE BIOPHARMA

Upon close of the transaction, the businesses of Xeris and Strongbridge will be combined under a new entity to be called Xeris Biopharma Holdings, Inc. (Xeris Biopharma Holdings).

Key Points: 
  • Upon close of the transaction, the businesses of Xeris and Strongbridge will be combined under a new entity to be called Xeris Biopharma Holdings, Inc. (Xeris Biopharma Holdings).
  • The minimum payment on the CVR per Strongbridge ordinary share is zero and the maximum payment is $1.00 in cash or Xeris Biopharma Holdings common stock, at Xeris Biopharma Holdings election.
  • The combination of Xeris and Strongbridge is expected to deliver compelling strategic and financial benefits including:
    Diversified and Increased Revenue Growth.
  • On close, Xeris shareholders will exchange each share of Xeris common stock they own for 1 share of Xeris Biopharma Holdings common stock.

Xeris Pharmaceuticals to Webcast Upcoming Presentations

Retrieved on: 
Monday, May 10, 2021
Biotechnology, General Health, Pharmaceutical, Health, Glucagon, Siricidae, Xeris, Forward-looking statement, Hypoglycemia, Medicine, Clinical medicine, Health

b'Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will participate in following upcoming virtual events:\nThe diaTribe Foundation Musings: Taking the Fear out of Hypoglycemia: Next-Generation Glucagon on May 13, 2021\nRBC Capital Markets Global Healthcare Conference on May 19, 2021\nJefferies Global Healthcare Conference on June 2, 2021\nThe above listed dates are subject to change.

Key Points: 
  • b'Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will participate in following upcoming virtual events:\nThe diaTribe Foundation Musings: Taking the Fear out of Hypoglycemia: Next-Generation Glucagon on May 13, 2021\nRBC Capital Markets Global Healthcare Conference on May 19, 2021\nJefferies Global Healthcare Conference on June 2, 2021\nThe above listed dates are subject to change.
  • Details on presentation times or changes to presentation dates can be found on the Company\'s website.
  • With Xeris\xe2\x80\x99 technology, new product formulations are designed to be easier to use by patients, caregivers, and health practitioners and help reduce costs for payers and the healthcare system.\nXeris is headquartered in Chicago, IL.
  • Any forward-looking statements contained in this press release speak only as of the date hereof, and Xeris expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.\nThe Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210510005622/en/\n'

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Friday, February 26, 2021
Diabetes, Pharmaceutical, Health, Siricidae, Articles, Albums, Xeris, Anna Vissi Live, Equity, Inducement rule, Subsidiary, Business

Xeris Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual's entering into employment with Xeris or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

Key Points: 
  • Xeris Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual's entering into employment with Xeris or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
  • The restricted stock units will vest over a period of four years in equal annual installments and are subject to the employees continued employment with Xeris or one of its subsidiaries.
  • All equity awards are subject to the terms and conditions of Xeris Inducement Equity Plan and forms of award agreements covering the grants.
  • Xeris (Nasdaq: XERS) is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world.

Xeris Pharmaceuticals to Webcast Upcoming Investor Conference Presentations

Retrieved on: 
Thursday, February 18, 2021
Diabetes, General Health, Pharmaceutical, Health, Software, Microsoft, Operating systems, Siricidae, Regulation Fair Disclosure, U.S. Securities and Exchange Commission, United States securities law, Caregiver, Xeris, LinkedIn, Instagram

With Xeris technology, new product formulations are designed to be easier to use by patients, caregivers, and health practitioners and help reduce costs for payers and the healthcare system.

Key Points: 
  • With Xeris technology, new product formulations are designed to be easier to use by patients, caregivers, and health practitioners and help reduce costs for payers and the healthcare system.
  • Xeris is headquartered in Chicago, IL.
  • For more information, visit www.xerispharma.com , or follow Xeris on Twitter, LinkedIn, or Instagram.
  • The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Friday, November 27, 2020
Medical Supplies, Health, Diabetes, Other Health, General Health, Pharmaceutical, Siricidae, Articles, Albums, Xeris, Anna Vissi Live, Equity, Subsidiary, NASDAQ, Inducement rule, Business

Xeris Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual's entering into employment with Xeris or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

Key Points: 
  • Xeris Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual's entering into employment with Xeris or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
  • The restricted stock units will vest over a period of four years in equal annual installments, and are subject to the employees continued employment with Xeris or one of its subsidiaries.
  • All equity awards are subject to the terms and conditions of Xeris Inducement Equity Plan and forms of award agreements covering the grants.
  • Xeris (Nasdaq: XERS) is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world.

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Friday, October 30, 2020
Diabetes, Pharmaceutical, Health, Siricidae, Privacy law, Digital rights, Human rights, Identity management, Xeris, Privacy, Medical privacy, Articles, Social issues, Applied ethics

Xeris Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual's entering into employment with Xeris or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

Key Points: 
  • Xeris Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual's entering into employment with Xeris or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
  • The non-qualified stock options are subject to the terms and conditions of Xeris Inducement Equity Plan and forms of award agreements covering the grants.
  • Xeris (Nasdaq: XERS) is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world.
  • With Xeris technology, new product formulations are designed to be easier to use by patients, caregivers, and health practitioners and help reduce costs for payers and the healthcare system.